Stay updated on Nivolumab and Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.
Latest updates to the Nivolumab and Ipilimumab in Melanoma Clinical Trial page
- Check4 days agoChange DetectedMelanoma is added as a related disease tag and MedlinePlus Genetics is listed as a related topic. These are supplemental navigation/resources and do not modify the study data or eligibility criteria.SummaryDifference0.1%
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe study location lists were updated to add multiple sites across the US, Canada, the UK, Australia, and Brazil, and to remove several existing locations.SummaryDifference2%
- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedMelanoma is removed from the Conditions section and the MedlinePlus Genetics related topic is removed.SummaryDifference0.1%
- Check47 days agoChange DetectedAdded Melanoma as a topic and a Related topics note (MedlinePlus Genetics); clarified that publications are auto-filled from PubMed. Removed the older PubMed publications note and updated the revision to v3.3.2.SummaryDifference0.1%
- Check54 days agoChange DetectedThe funding-status notice at the top of the ClinicalTrials.gov page has been removed; the study details, endpoints, and locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check69 days agoChange DetectedMelanoma and MedlinePlus Genetics related topics were removed from the page's related topics section.SummaryDifference0.3%
Stay in the know with updates to Nivolumab and Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.